CTX

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Retrieved on: 
목요일, 6월 6, 2024
Health, General Health, CTX, Proxy, Shareholder, OTC, TSX, Special

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024.

Key Points: 
  • Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024.
  • The detailed results of the votes received by proxy are as follows:

Citi Trends Announces First Quarter Fiscal 2024 Results

Retrieved on: 
화요일, 6월 4, 2024
Retail, Home Goods, Specialty, Fashion, Citigroup, Interim, CTRN, Citi Trends, CTX, GAAP, History, Seipel, Share repurchase, African Americans, Growth, Mobile phone

Citi Trends, Inc. (NASDAQ: CTRN), a leading specialty value retailer of apparel, accessories and home trends for way less spend primarily for African American and multicultural families in the United States, today reported results for the first quarter ended May 4, 2024.

Key Points: 
  • Citi Trends, Inc. (NASDAQ: CTRN), a leading specialty value retailer of apparel, accessories and home trends for way less spend primarily for African American and multicultural families in the United States, today reported results for the first quarter ended May 4, 2024.
  • The quarter was further highlighted by gross margin expansion of 160 basis points compared to last year.
  • David shaped and built our strong purpose driven Citi Trends culture while leading the company through some of the most challenging consumer environments in recent history.
  • Our best wishes to David!”
    In the first quarter of fiscal 2024, the Company did not repurchase any shares of its common stock.

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
수요일, 5월 8, 2024
Pharmaceutical, Health, Clinical Trials, NDA, Depreciation, New Drug Application, CTX, CHMP, Cholestatic pruritus, Webcast, Cholestasis, VISTAS, Disease, Patient, Event, PFIC, Interim, Medication, Growth

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2024 and provided a business update.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2024 and provided a business update.
  • LIVMARLI first quarter net sales were $42.8 million, representing 47% growth compared to first quarter 2023.
  • Total revenue for the quarter ended March 31, 2024, was $69.2 million compared to $31.6 million for the quarter ended March 31, 2023.
  • Total operating expenses were $95.7 million for the quarter ended March 31, 2024, compared to $58.7 million for the quarter ended March 31, 2023.

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Retrieved on: 
월요일, 4월 8, 2024
Patient, Cerebrovascular disease, Stroke, Accelerated approval (FDA), European Medicines Agency, Doctor of Philosophy, Osteomalacia, PROMIS, Therapy, Conditional, Natural history, CTX, Pros, ADAS, Risk, DSM-IV codes, Cohort, Aes, Alkaline phosphatase, Rickets, EMA, PXE, Safety, Epilepsy, Clinical trial, Food, Hospital, Disability, BSAP, Cardiovascular disease, Disease, PD, Paresis, Consultant, Hypophosphatemia, Fatigue, Survivor, Sclera, FDA, Observational study, Pyrophosphate, Choroid, Incidence, Retina, Biomarker, Life, Event, Medical imaging

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency (PXE, pseudoxanthoma elasticum) and ENPP1 Deficiency.

Key Points: 
  • “We are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • The patients were assigned to three dose cohorts of INZ-701: 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=4).
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.

GitGuardian Announces New Software Composition Analysis Module

Retrieved on: 
화요일, 3월 26, 2024
Health, Organization, CLI, PHP, CTX, SCA, Software, AWS, SBOM, Software Composition Analysis, Intellectual property, Government, Risk management

PARIS and BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- GitGuardian , the world leader in automated secrets detection and remediation, released today its Software Composition Analysis (SCA) module.

Key Points: 
  • PARIS and BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- GitGuardian , the world leader in automated secrets detection and remediation, released today its Software Composition Analysis (SCA) module.
  • Open-source software has transformed software development, providing developers access to a vast pool of reusable components.
  • "If one of your buried dependencies becomes vulnerable, the blast radius could be gigantic," said Eric Fourrier, CEO of GitGuardian.
  • GitGuardian’s product suite addresses this gap by integrating a range of security tools, including Secrets Detection, Public Monitoring, Software Composition Analysis, Infra as Code Security, and Honeytoken.

Crescita Reports Q4 and Fiscal 2023 Results

Retrieved on: 
수요일, 3월 13, 2024
General Health, Pharmaceutical, Health, ART, Indian stock exchange, Financial statement, CTX, Face, Agreement, Amazon (company), International, International Financial Reporting Standards, Pharmacy, Toronto Stock Exchange, TSX, OTC, Traction, Collection, Marketing, Conversation, Video game

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2023 (“Q4-2023” and “F2023”).

Key Points: 
  • Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2023 (“Q4-2023” and “F2023”).
  • Commenting on the Company's results for the fourth quarter and full year 2023, Crescita's President and Chief Executive Officer, Serge Verreault, said:
    “2023 was a challenging year for Crescita, marked by headwinds in our manufacturing segment.
  • Certain manufacturing orders initially scheduled to be delivered in the second half of fiscal 2023 were, in part, deferred to 2024, and some cancelled, contributing to a material decrease in our manufacturing segment revenue for Q4-2023 and fiscal 2023, compared to the same periods of 2022.
  • During fiscal 2023, 719,203 Common Shares were repurchased for cancellation, at an average price of $0.55 per share for total cash consideration of $393.

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Retrieved on: 
수요일, 2월 28, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, International, New Drug Application, FDA, Food, CTX, Growth, Primary sclerosing cholangitis, PDUFA, PFIC, Event, Food and Drug Administration, Primary biliary cholangitis, Webcast, Patient, Medication, NDA, Pharmaceutical industry

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2023 and provided a business update.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2023 and provided a business update.
  • 2023 LIVMARLI net product sales totaled $141.8 million, representing approximately 89% growth over 2022 net product sales.
  • As of December 31, 2023, Mirum had cash and cash equivalents of $286.3 million.
  • The foregoing financial information is unaudited and subject to change, and actual results may vary from the foregoing.

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Retrieved on: 
월요일, 1월 29, 2024
WFIA, CTX, Cingulata, Regulation D, Sale, Act, Security (finance)

The closing price of Cingulate’s common stock on Nasdaq on January 24, 2024 was $4.35 per share.

Key Points: 
  • The closing price of Cingulate’s common stock on Nasdaq on January 24, 2024 was $4.35 per share.
  • Cingulate, Cingulate Therapeutics LLC (CTx) and WFIA entered into a Note Conversion Agreement on January 25, 2024, pursuant to which WFIA agreed to convert the remaining $3.0 million of principal under its outstanding note, plus all accrued interest thereon, or $3.3 million total, into pre-funded warrants (“the Pre-Funded Warrants”) to purchase 687,043 shares of Cingulate’s common stock.
  • The Pre-Funded Warrants have no expiration date and are exercisable immediately at an exercise price of $0.0001 per share, subject to a beneficial ownership blocker of 19.99%.
  • Following the conversion, all debt and accrued interest with WFIA is paid in full.

Powered by Its Industry-Leading Comprehensive Multi-Modal Database, Caris Life Sciences to Showcase Research at ASCO Gastrointestinal Cancers Symposium 2024

Retrieved on: 
수요일, 1월 17, 2024
Panitumumab, MSI, NGS, Patient, EGFR, Research, Cancer, MD, CTX, ASCO, Diagnosis, Cetuximab, CCA, AI, Society, NCI, Prognosis, TMB, FGFR2, Immunotherapy, FACP, Mutation, MBA, APC, Biomarker, CRC, POA, Abstract, GI, Medicine, Prevalence

IRVING, Texas, Jan. 17, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 11 studies across six solid tumor types at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 18-20, 2024 in San Francisco. The findings demonstrate the power of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.  

Key Points: 
  • "We are proud to again present a wide array of precision oncology research at this year's ASCO GI.
  • Strikingly, patients with early-onset CCA experience better outcomes from immunotherapy even though immune-oncology-relevant markers like MSI and TMB favors average-onset CCA.
  • Two posters use EGFRi-treated CRC samples from the Caris multi-modal database to explore two promising possibilities: APC mutation status and CTX sensitivity score (CTX-S).
  • The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Carbon Trade eXchange India (CTX India) to Launch

Retrieved on: 
목요일, 11월 23, 2023
Technology, Other Energy, Finance, Alternative Energy, Energy, Professional Services, Environment, Sustainability, Software, Agriculture, Fintech, Natural Resources, Green Technology, Climate Change, Carbon, Sale, Broker, SASA, Green Man, White label, UNFCCC, Biophysical environment, CTX, Registry, Adama Agricultural Solutions, Cryptocurrency

In another historic step for the world’s first Voluntary Carbon Exchange, CTX has partnered with SASA ENVIRO , a revered Chennai-based Environmental and Agricultural Solutions provider.

Key Points: 
  • In another historic step for the world’s first Voluntary Carbon Exchange, CTX has partnered with SASA ENVIRO , a revered Chennai-based Environmental and Agricultural Solutions provider.
  • This National Master Licensee will also operate a White Label version of the CTX platform to deliver an Indian operated, owned, and branded version of the world’s leading global Voluntary Carbon platform.
  • High Quality Carbon Credits issued by the Various Registries interfaced with CTX can be listed via CTX India platform and CTX globally, priced by sellers, with no costs to list their credits, with only a small fee on the sale.
  • We will be rapidly expanding the CTX India Business Development team, after training by CTX Global in December.”